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Practice
The prevalence of active asthma in the United King-
dom is 5.8% according to data from the quality and 
outcomes framework of the new general medical 
services contract (which allocates 45 points for caring 
for patients with asthma). There are still about 1500 
deaths a year from asthma in the UK, many of which 
may be preventable, and asthma affects about eight 
million people in the UK at some stage in their lives.
What should i already know about this condition?
Asthma is a variable condition. You can make the diag-
nosis by noting a history of variable symptoms, con-
firmed by variability of peak flow (or spirometry):
• ≥20% variability in peak expiratory flow rate 
(PEFR) (≥60 l/min) on three days in a week for at 
least two weeks
• ≥20% improvement in PEFR (or 15% with a 
200 ml improvement in forced expiratory volume 
in one second (FEV1)) after treatment—for example,
10 minutes after inhalation of high dose β2 agonist
(through a spacer)
After a six week course of inhaled corticosteroids
After 14 days of 30 mg prednisolone
• ≥20% decrease in PEFR after challenge with a 
trigger factor (such as after exercise).
What new evidence do i need to know about?
Telephone reviews
Building on a previously published trial,1 this study 
randomised 194 adults with asthma in the south west 
of England to telephone review or surgery review 
over 12 months.2 Patients in the telephone group were 
contacted every six months and asked the Royal Col-
lege of Physicians’ three morbidity index questions 
plus two other questions about hospital admissions 
and treatment in intensive care. An action plan was 
agreed for those considered to be at low risk. A sur-
gery appointment was arranged if the patient answered 
“yes” to any of the questions.
Control of asthma was similar in both groups, 
with a mean cost of £210 per patient per year in the 
telephone group compared with £334 in the clinic 
group.
Bottom line—Telephone reviews may be as effec-
tive as face to face reviews and are cost effective, so 
it is surprising that telephone review is not permit-
ted under the quality and outcomes framework. The 
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rationale is that inhaler technique cannot be checked 
over the telephone.
IMPACT trial
In this study 225 adults with mild asthma who did not 
smoke were randomised to one of three treatment 
arms—regular budesonide, regular oral zafirlukast (20 
mg twice daily), or intermittent use of inhaled budeso-
nide.3 Primary outcome was peak flow measured in 
the morning.
Patients in all three groups had similar increases in 
morning peak flow (of about 7.8%) and similar rates of 
exacerbations, though those taking intermittent treat-
ment experienced more symptoms and markers of 
bronchial inflammation. Patients using intermittent 
treatment took budesonide for an average of only 0.5 
weeks a year.
Bottom line—This is an exploratory study, which 
needs to be confirmed, but it raises the possibility 
that some patients with mild persistent asthma could 
be treated with short, intermittent courses of inhaled 
steroids.
How many patients with asthma have rhinitis?
This study, of 7219 patients with asthma in the UK, 
found that 76% reported symptoms of rhinitis (blocked 
or runny nose, itchy eyes, and sneezing).4 Of this 76%, 
half said that their rhinitis made their asthma worse, 
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Practical tiPs
• Ask specific questions about asthma control, such as the 
Royal College of Physicians’ three questions: people who 
are used to living with asthma tend not to volunteer their 
symptoms unless asked specifically
• Step up treatment if symptoms are not controlled: step 
down if your patient’s asthma is stable
• People who learn how to control their asthma are less 
likely to have exacerbations. Every encounter with medical 
services is an opportunity to review, reinforce, and extend 
patients’ knowledge and skills
• Patients’ action plans should include details of their 
asthma drugs, advice about when to take further action, 
what to do if symptoms get worse, when to return to usual 
doses, and when to seek urgent medical help
• Rhinitis is a very common comorbidity. Ask patients 
with asthma about nasal symptoms, and ask patients with 
rhinitis about wheeze
Practice
58% reported seasonal rhinitis whereas the others 
reported constant symptoms, and only 54% were 
being prescribed a nasal corticosteroid.
Bottom line—There is growing evidence of the impor-
tance of the overlap between rhinitis and asthma. You 
should ask all patients with asthma if they have symp-
toms of rhinitis.
The salmeterol multicentre asthma research trial
This trial found that salmeterol may increase the 
risk of severe and life threatening exacerbations of 
asthma, especially in African-American patients, and 
in those who are not prescribed concomitant inhaled 
corticosteroids.5 6 Whether this risk is due to genetic 
factors, or patient behaviours leading to poor out-
comes is not known.
Bottom line—Long acting β agonists are effective in 
reducing asthma symptoms, but clinicians should pre-
scribe, and patients be counselled to take, concomitant 
inhaled corticosteroids.
Cochrane review
This review looked at all randomised controlled trials 
that included children older than 2 years who were 
given inhaled β2 agonists for chronic cough (that is, 
cough lasting more than three weeks).7 Salbutamol 
showed no benefit over placebo.
Bottom line—Salbutamol may not be useful for chil-
dren with chronic cough.
What new guidelines have been produced in the past 
two years?
The British Thoracic Society (BTS) and Scottish Intercol-
legiate Guidelines Network (SIGN) guidelines on the 
management of asthma with web based annual updates
See box for management advice based on these 
guidelines.8 Important points are
• Introduce inhaled corticosteroids if patients have
  — Had an exacerbation of their asthma in the 
past two years
 — Symptoms needing a β agonist at least three 
times a week
 — Symptoms at least one night a week
• Exercise induced asthma is often a sign of poor 
control
• Inhaled corticosteroids are thought to be safe to 
a maximum daily dose equivalent to <800 µg 
beclometasone for adults and <400 µg for 
children. At regularly higher doses, adults may 
be at increased risk of osteoporosis, and children 
may be at risk of short term growth suppression 
or adrenal insufficiency
• Long acting β agonists are now used at step 3  
(see box) instead of increasing the inhaled 
corticosteroid dose further.
• Self management plans are important. About 90% 
of asthma exacerbations occur relatively slowly. 
For example, it is common to have symptoms 
during the night for several nights before hospital 
admission
• Using a pressurised metered dose inhaler and 
spacer is at least as good as a nebuliser for treating 
mild and moderate exacerbations
• Occupational asthma accounts for 9-15% of 
adult onset asthma. You should ask adults with 
new onset asthma or re-emergence of childhood 
asthma if their symptoms improve on days away 
from work. If so, refer them to an occupational 
health doctor.
Practical management tips
Aim to keep your patient on the lowest effective dose 
of inhaled corticosteroid that will prevent symptoms. 
Inhaled corticosteroids are often used in inappropri-
ate doses. 
If your patient’s asthma is well controlled you should 
step down treatment (reduce the dose by 25-50% every 
three months). Only 5-10% of people with asthma will 
need high dose corticosteroids.
Equally, concordance with use of regular inhaled 
corticosteroids is poor, and many patients are 
undertreated.
Use the three morbidity index questions recom-
mended by the Royal College of Physicians to assess 
symptoms of asthma in the past week or month:
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Summary of the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines 
Network (SIGN) guidance on managing asthma8
Step 1—Mild intermittent asthma
• Inhaled short acting β2 agonist as required
Step 2—Regular prophylactic therapy
• Add inhaled corticosteroid, starting at dose appropriate to severity of asthma
• Children aged <5 years—Start at dose equivalent to beclometasone 200-400 µg/day 
(though a higher nominal dose may be needed if drug delivery is difficult) or, if inhaled 
corticosteroid cannot be used, start a leucotriene receptor antagonist 
• Children aged 5-12 years—Start at dose equivalent to beclometasone 200-400 µg/day 
(200 µg is appropriate for many patients) or, if inhaled corticosteroid cannot be used, start 
another prophylactic drug
• Teenagers and adults—Start at dose equivalent to beclometasone 200-800 µg/day (400 µg 
is appropriate for many patients)
Step 3—Additional therapy
• Children aged <2 years—Consider referring to a respiratory paediatrician
• Children aged 2-5 years—Consider trial of leucotriene receptor antagonist
• Older children and adults—Add inhaled long acting β2 agonist and assess response:
 If good response, continue treatment
 If some response but asthma control still inadequate, increase inhaled corticosteroid dose 
to equivalent of 400 µg (if not already at this dose)
 If no response, stop long acting  β2  agonist, increase inhaled corticosteroid dose to 
equivalent of 400 µg, and, if necessary, start trial of other additional therapy (such as 
leucotriene receptor antagonist or slow release theophylline)
Step 4—Persistent poor control
• Children aged <5 years—Refer to respiratory paediatrician
• Children aged 5-12 years—Increase inhaled corticosteroid dose to equivalent of ≤800 µg
• Teenagers and adults—Consider trials of:
 Increasing inhaled corticosteroid dose to equivalent of ≤2000 µg
 Adding a fourth drug such as leucotriene receptor antagonist, slow release theophylline, or 
oral β2 agonist
Step 5—Continuous or frequent use of oral corticosteroids
• Patients whose asthma is still not controlled should be referred to a specialist 
for assessment and consideration of further options including high dose inhaled 
corticosteroids, frequent or regular oral corticosteroids, and anti-E immunoglobulin
Practice
• “Have you had your usual asthma symptoms 
during the day, such as cough, wheeze, chest 
tightness, or breathlessness?”
• “Have you had any difficulty sleeping because of 
your symptoms, including cough?”
• “Has your asthma interfered with your usual 
activities (such as housework, work, or school)?”
Measuring PEFR is a useful tool for making a diag-
nosis, and assessing how well a patient’s asthma is 
controlled. It is essential in objectively assessing the 
severity of an acute attack, when it should be com-
pared with the patient’s best achieved peak flow. 
Ideally, all adults should have their best peak flow 
measured every five years to compensate for decreas-
ing lung function with age. Children who are still 
growing should be assessed more frequently—for 
example, as part of an annual asthma review.
Include the following information in a patient’s 
action plan: details of asthma drugs including names, 
doses, and side effects; advice about when to take 
further action (for example, based on the pattern of 
their symptoms or peak flow measurements); what 
to do if symptoms get worse; when to return to usual 
doses; and when to seek urgent medical help.
Increasing the dose of inhaled corticosteroid during 
an exacerbation is an essential component of suc-
cessful asthma action plans. One study showed that 
increasing the dose fivefold was effective.9 
Rhinitis is a common comorbidity. Ask patients 
with asthma about nasal symptoms, and ask patients 
with rhinitis about wheeze.
Consider keeping a register of high risk patients with 
asthma. These include those who have been admitted 
to hospital with asthma in the past year, those with 
“brittle” asthma (condition tends to deteriorate rapidly 
during an exacerbation with little warning), and those 
who have ever been admitted to an intensive care unit 
with asthma.
It is marginally cheaper to prescribe combined 
 corticosteroid and long acting β2 agonist inhalers 
rather than prescribing them individually, and this 
prevents the potential danger of non-compliance with 
the inhaled steroid. However, it prevents the flexibility 
of adjusting the dose of the drugs independently.
When should i refer my patient?
You should refer your patient if you are unsure of 
the diagnosis, especially in infants, or if you suspect 
that asthma may be related to your patient’s working 
conditions (occupational asthma).
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Commonly asked questions—answered by our experts
At what age can we safely diagnose asthma (as opposed to viral induced wheeze) in a toddler?
It is difficult to be certain whether a wheezy toddler has asthma, but you should consider following a structured diagnostic 
process: 
• An appropriate history—Episodic cough and wheeze, especially with a personal or family history of atopy, are  
suggestive. Viral associated wheeze is often related to passive smoking and other causes of babies being small for their 
birth date
• Objective evidence—Lung function tests are impractical, so wheeze heard by a healthcare professional should be noted as 
objective confirmation of the parents’ description
• Response to treatment—Improvement in symptoms supports a diagnosis of asthma, but subsequent withdrawal of 
treatment is necessary to exclude coincidental improvement. A clear response to bronchodilation is helpful, but for more 
chronic symptoms a course of inhaled corticosteroids will be more appropriate. The starting dose suggested for children  
may need to be increased for infants because of the practical problems of delivering adequate doses to the lung: some 
authors suggest up to 800 µg daily for two months.10 A poor response suggests that asthma is unlikely and you can stop 
treatment.
Should we double inhaled corticosteroids as part of an asthma action plan?
Empowering people to adjust their dose of inhaled corticosteroid in response to symptoms or peak flows is an effective part 
of action plans.11 In the real world, where patients reduce or even stop their inhaled corticosteroids between exacerbations, it 
is appropriate to remind patients to reinstate prophylactic treatment when their asthma control deteriorates. For patients with 
low maintenance doses of inhaled corticosteroids, the dose should be increased substantially if control worsens. Patients 
with more severe asthma who are already regularly taking high doses of inhaled corticosteroids may be better advised to start 
oral corticosteroids.
What are the alternatives to long acting β agonists as additional therapy?
Before increasing treatment, assess the clinical situation, checking diagnosis, inhaler technique, concordance with treatment, 
possible environmental triggers and concomitant rhinitis.
The BTS-SIGN guidelines recommend long acting β  agonists as the first choice for additional therapy for adults and 
older children. This statement does not, however, take into account the complexity of tailoring treatment to individual 
circumstances.
• In light of recent concerns about increased risk of severe asthma attacks in patients taking long acting β agonists, it is 
important to optimise inhaled corticosteroid treatment
• Leucotriene antagonists can reduce the symptoms of rhinitis, and so may be particularly suitable as additional therapy for 
patients whose asthma has slipped out of control during the hay fever season 
• Both long acting β agonists and leucotriene antagonists effectively reduce exercise induced asthma. A patient’s preference 
for a tablet or an inhaler may be an important factor when choosing a treatment
• In preschool children long acting β agonists seem to be less effective, and leucotriene antagonists may be the better  
option
Practice
It is also reasonable to refer if asthma control is not 
achieved by stepping up treatment to step 4 (adults 
and children) or step 3 (children under 5 years) see 
Summary of the British Thoracic Society (BTS) and 
the Scottish Intercollegiate Guidelines Network 
(SIGN) guidance.
common pitfalls
Many people with asthma are not receiving their 
 prescribed treatment because of poor concordance 
with regular treatment and poor inhaler technique. 
You should try to discuss concordance in a non-
 judgmental way and check that patients know how 
to use their inhaler correctly before you change their 
treatment. (The Asthma UK website (www.asthma.
org.uk) has an interactive demonstration of inhaler 
technique.)
Do not underestimate seasonal asthma. There is a 
strong link between asthma and hay fever, and deaths 
from asthma in young adults peak during the pollen 
season.12 You should advise these patients to ask for 
help early when their symptoms worsen, and tell them 
about the link between asthma and rhinitis.
There is often confusion between chest infections 
and acute asthma. Acute asthma is commonly trig-
gered by viral infections or allergens. You should not 
routinely prescribe antibiotics.
Delaying treatment is the most common prevent-
able factor in asthma related deaths. This is often 
because the doctor or patient underestimates sever-
ity. You should use and record objective measures of 
severity such as peak flow measurements.
Do not prescribe long acting β agonists for patients 
with asthma without also prescribing inhaled 
 corticosteroids.
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ADDITIoNAl eDuCATIoNAl ReSouRCeS
• British Thoracic Society: www.brit-thoracic.org.uk
• General Practice Airways Group: www.gpiag.org
• Asthma UK: www.asthma.org.uk
• Clinical Evidence: www.clinicalevidence.com
• Best Treatments: www.besttreatments.co.uk
• Drugs and Therapeutics Bulletin: www.dtb.org.uk
• Scottish Intercollegiate Guidelines Network: www.sign.
ac.uk
• Royal College of Physicians: www.rcplondon.ac.uk
• NetDoctor: www.netdoctor.co.uk
• BMJ Learning: www.bmjlearning.com 
Asthma in adults: diagnosis
Childhood asthma: diagnosis and treatment
She was brought in one night from a distant health 
centre from our rural Tanzanian hospital. No fetal 
heart beat could be found, so the on-call doctor 
decided to allow nature to take its course. In the 
morning when I reviewed her I thought I heard a 
weak and rapid fetal heart beat. The mother was pale 
and sick, and we started to resuscitate her. She had no 
contractions and was only 5 cm dilated, so we agreed 
to take her to theatre to save the mother and possibly 
the baby. 
Arriving in theatre, the anaesthetist looked at her 
and said he didn’t think we should operate—he didn’t 
relish a death on the table. She had indeed reached 
the gasping stage, seemed to gasp for the last time, and 
looked beyond our help. Believing that the baby might 
still be alive, I threw on some gloves and grabbed a 
knife. The patient had the typical peri-mortem look 
as I cut, there was no bleeding, and her flesh had the 
grey-white look of death. I removed two macerated 
babies followed by numerous clots, confirming a 
concealed abruption. With a deflated uterus giving her 
diaphragm space, the patient then gasped deeply, and 
the anaesthetist, his interest renewed, started vigorous 
resuscitation. I completed her hysterectomy as her 
uterus was beyond saving, and we poured blood into 
her. 
Five days later she went home cheerful and pink. 
Resuscitation with a full uterus is supposed to be 
difficult, but even when it seems too late, keeping 
going can produce miraculous results. Don’t give up.
Sally edmonds obstetrician, Hospitali Teule, Muheza, Tanga, 
Tanzania bennsal@teule.org.uk 
Bashiri Mmbare anaesthetist
Don’t give up
